Pfizer has submitted a biologics licence application to the US Food and Drug Administration (FDA) for approval of its vaccine candidate bivalent recombinant LP2086 (rLP2086) to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people aged ten to 25.

Pfizer vaccine research and development senior vice-president Dr Emilio Emini said: "There is an urgent public health need to help prevent meningococcal B disease through vaccination, and we will continue to work closely with the FDA in our efforts to advance our vaccine candidate."

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Pfizer’s bivalent rLP2086 contains two recombinant versions of the LP2086 antigen, one representative for each of the two known genetic subfamilies of the antigen.

"There is an urgent public health need to help prevent meningococcal B disease through vaccination."

The company’s investigational meningococcal B vaccine targets LP2086, or factor H binding protein, which is found on the surface of the meningococcal B bacterium.

At present, the company is conducting a clinical development programme for bivalent rLP2086. This programme includes both Phase II and Phase III studies evaluating more than 20,000 participants, with 14,000 of these receiving the investigational vaccine.

In November 2012, the company initiated the Phase III programme. In addition, immunogenicity and safety studies are also ongoing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In March, the FDA had granted breakthrough therapy designation for bivalent rLP2086 based, in part, on data from clinical trials studying the safety and immunogenicity of the vaccine.